PALO ALTO, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc., (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback